Homozygous inactivation of *CHEK2* is linked to a familial case of multiple primary lung cancer with accompanying cancers in other organs

Yoji Kukita,¹ Jiro Okami,² Noriko Yoneda-Kato,³ Ikuko Nakamae,³ Takeshi Kawabata,⁴ Masahiko Higashiyama,² Junya Kato,³ Ken Kodama,² and Kikuya Kato¹

¹Department of Molecular and Medical Genetics, Research Institute, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka 537-8511, Japan; ²Department of General Thoracic Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka 537-8511, Japan; ³Department of Tumor Cell Biology, Graduate School of Biological Sciences, Nara Institute of Science and Technology, Ikoma, Nara 630-0101, Japan; ⁴Institute for Protein Research, Osaka University, Suita, Osaka 565-0871, Japan

Abstract In clinical practice, there are a number of cancer patients with clear family histories, but the patients lack mutations in known familial cancer syndrome genes. Recent advances in genomic technologies have enhanced the possibility of identifying causative genes in such cases. Two siblings, an elder sister and a younger brother, were found to have multiple primary lung cancers at the age of 60. The former subsequently developed breast cancer and had a history of uterine myoma. The latter had initially developed prostate cancer at the age of 59 and had a history of colon cancer. Single-nucleotide polymorphism (SNP) genotyping revealed that ~10% of the genomes were homozygous in both patients. Exome sequencing revealed nonsynonymous mutations in five genes in the runs of homozygosity: *CHEK2*, *FCGRT*, *INPP5J*, *MYO18B*, and *SFI1*. Evolutionary conservation of primary protein structures suggested the functional importance of the *CHEK2* mutation, p.R474C. This mutation altered the tertiary structure of CHK2 by disrupting the salt bridge between p.R474 and p.E394. No such structural changes were observed with the other mutated genes. Subsequent cell-based transfection analysis revealed that CHK2 p.R474C was unstable and scarcely activated. We concluded that the homozygous *CHEK2* variant was contributory in this case of familial cancer. Although homozygous inactivation of *CHEK2* in mice led to cancers in multiple organs, accumulation of additional human cases is needed to establish its pathogenic role in humans.

Corresponding author: kikuya@kato.nifty.jp

© 2016 Kukita et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted reuse and redistribution provided that the original author and source are credited.

Ontology terms: neoplasm of the lung

Published by Cold Spring Harbor Laboratory Press

doi: 10.1101/mcs.a001032

INTRODUCTION

There are various degrees of inherited cancer susceptibility: rare high-penetrance mutations, rare disease-causing variants, and common susceptibility alleles (Fletcher and Houlston 2010). In particular, the analysis of rare high penetrance mutations has contributed to understanding the molecular mechanisms of carcinogenesis. Autosomal-dominant syndromes such as familial adenomatous polyposis and retinoblastoma have led to the discovery of tumor-suppressor genes. Hereditary cancers can be either specific to a certain organ or present in multiple organs. Examples of the former are breast cancer with *BRCA1/BRCA2* mutations and retinoblastoma with *RB1* mutations. An example of the latter is Li–Fraumeni

syndrome caused by mutations in *TP53* (Malkin et al. 1990). Lynch syndrome is caused by defective DNA mismatch repair enzymes (Vasen et al. 1999) and usually manifests as colorectal cancer but often accompanies malignancies in other organs. However, in clinical practice, there are a number of cancer patients with clear family histories, but the patients lack mutations in known familial cancer syndrome genes. Recent advances in genomic technologies like exome and whole-genome sequencing have enhanced the possibility of identifying causative genes in such cases.

In this report, we describe the exome analysis of siblings who suffered from multiple primary lung cancer as well as cancers in other organs. The analysis revealed that homozygous inactivation of *CHEK2* was linked to the case.

RESULTS

Description of Patients

The family tree of the two patients is shown in Figure 1. Their parents suffered from and died of cancers in various organs. The male patient, FL1, had a history of colon cancer and developed prostate and multiple primary lung cancer with no history of smoking. At the age of 59, he was diagnosed with prostate cancer (Gleason score $4 + 3 = 7$, cT2N0M0), and hormone therapy was initiated. At the age of 60, left lobectomy was performed as part of the treatment for multiple primary lung cancer. His major lesion was located at LS8, measuring 1 cm in diameter, and histological analysis revealed it to be a minimally invasive adenocarcinoma.

The female patient, FL2, was 6 years older than the male patient. At the age of 38, she was diagnosed with uterine myoma and developed multiple primary lung cancer at the age of 60 with no history of smoking. Three primary tumors were located in the right lobe. The loci, diameters, and histology of these lesions were as follows: RS1, 4 cm, invasive adenocarcinoma; RS4, 1 cm, minimally invasive adenocarcinoma; and RS6, 1 cm, adenocarcinoma in situ. These lesions were surgically resected. This patient subsequently developed multiple primary lung cancer in the left lobe and breast cancer at the age of 71. The loci, diameters, and histology of the lung tumors were as follows: LS8, 2.5 cm, invasive adenocarcinoma, acinar pattern predominant; LS8, 1.9 cm, invasive adenocarcinoma, papillary pattern predominant; LS8, 2 cm, invasive adenocarcinoma, papillary pattern predominant; and LS10, 1.8 cm, invasive adenocarcinoma, papillary pattern predominant. The lung and breast tumors were

Figure 1. Family tree of the patients.

Figure 2. Microscopic view of multiple lung cancers. Hematoxylin and eosin staining and immunostaining with TTF1 and Napsin A. (A) FL1. (B) FL2. Both exhibit histology of invasive adenocarcinoma.

surgically resected. The lung cancer *EGFR* mutation status was L858R and wild type, probably because of heterogeneity among tumor nodules. Histological and molecular analysis of the breast cancer revealed it to be an invasive ductal carcinoma with a predominant ductal component, estrogen receptor–negative, progesterone receptor–negative, and Her2-positive. Micrographic views of both patients' lung cancers are shown in Figure 2.

Homozygosity Mapping

We analyzed the general structures of the two patients' genomes with single-nucleotide polymorphism (SNP) genotyping. As part of the routine analyses, we performed homozygosity mapping using the SNP-genotyping data, which involved screening for runs of homozygous genotypes in each sibling. The total lengths of homozygous segments (>1 Mb) in autosomal chromosomes were 217 and 315 Mb for FL2 and FL1, respectively (Table 1; Fig. 3). Because ~10% of genomic regions were homozygous for both patients, we concluded that there was consanguineous marriage between their parents. Overlapping homozygous regions (63 Mb) between them were candidate regions for searching causative mutations for this family. For Chromosome X, 13 runs of homozygosity (total length 29 Mb) were detected in the female patient FL2, which were identified as possible targets. No aberrant copy-number variants were detected (Fig. 3).

Exome Sequencing

Next, to identify causative mutations in coding regions, we performed whole-exome sequencing. After we removed polymerase chain reaction (PCR)-duplicated reads from the more than 190 million reads for each sibling, we obtained sequence data on protein coding regions with a mean depth of 95× (Table 2). Approximately 10,000 variants with amino acid changes were detected in each sibling, and 80% of them were shared between the siblings (Table 3). Of the novel variants identified using public variant databases (the Database for Short Genetic Variations [dbSNP], phase 1 of the 1000 Genome Project, and the Exome Sequencing Project of the National Heart, Lung, and Blood Institute [NHLBI]), five missense

Table 1. Runs of homozygosity

Sample	Segments	Mean (bp)	Total (bp)
FL1	65	4,850,810	315,302,625
FL2	59	4,167,608	245,888,862

Data for Chr X were not included for FL1 because he is male.

Figure 3. Patients’ runs of homozygosity. Patient siblings were analyzed using single-nucleotide polymorphism (SNP) arrays, and runs of homozygous genotypes were screened using PLINK. The circles, starting from outside going inward, represent the human chromosomes (Chr 1–22, X), runs of homozygosity (red bars, FL2; blue bars, FL1), B allele frequency (BAF) (red plots, FL2; blue plots, FL1), and log R ratio (LRR) (orange plots, FL2; light blue plots, FL1). The value range of the BAF plot is 0 to 1. The value range of LRR plot is –4 to 2 (“0” is marked by black lines).

variants were found in the runs of homozygosity detected above. Single missense mutations were identified in *CHEK2* (Fig. 4A), *FCGRT*, *INPP5J*, *MYO18B*, and *SFI1* (Table 4). The variants, with the exception of *MYO18B*, have been recorded in ClinVar (Landrum et al. 2016; <http://www.ncbi.nlm.nih.gov/clinvar/>) with low allele frequencies (< 0.03%), and their “Clinical Significance” in the database was “Uncertain significance” (*CHEK2*) or “NA” (*FCGRT*, *INPP5J*, and *SFI1*). None of them have been recorded in the Human Gene Mutation Database (HGMD) public entries (<http://www.hgmd.cf.ac.uk/ac/index.php>).

Table 2. Exome sequencing statistics

Sample	Total reads	Mapped reads	Mapping rate	On targets (bases)	Mean depth
FL1	195,020,136	191,742,948	98.3%	4,929,447,566	95.05
FL2	198,040,764	194,986,150	98.5%	4,922,943,301	94.93

Table 3. Variants detected by exome sequencing

Variants	FL1	FL2	Shared
Nonsynonymous SNV	9072	9212	7282
Stopgain SNV	81	80	56
Stoploss SNV	19	18	15
Splicing SNV	74	65	54
Nonframeshift insertion	82	83	61
Frameshift insertion	105	104	89
Splicing insertion	41	41	34
Nonframeshift deletion	98	96	67
Frameshift deletion	90	106	77
Splicing deletion	19	18	16
Total	9681	9823	7751

SNV, single-nucleotide variant.

Evaluation of Candidate Genes by Primary and Tertiary Structures

First, the effects of these missense variants were predicted using the Variant Effect Predictor at Ensembl (McLaren et al. 2010), for which SIFT (Sorting Intolerant from Tolerant) (Kumar et al. 2009) and PolyPhen (Polymorphism Phenotyping) (Adzhubei et al. 2010) are used. Three variants in *CHEK2*, *FCGRT*, and *SFI1* were predicted to be “deleterious” or “probably damaging” by SIFT or PolyPhen. For these three genes, we examined whether the amino acid substitutions affected protein function based on evolutionary conservation using SIFT. *SFI1* did not have enough homologs deposited in the UniProt database and could not be subjected to the analysis. p.R474 of *CHK2* (protein corresponding to *CHEK2*) was conserved in 98% of homologs. p.R218 of *FCGRT* was less conserved and appeared only in 14% of the homologs. Other amino acids such as histidine (27%) and cysteine (12%) also appeared in the homologs at this position.

Second, we examined how the amino acid substitutions affect the tertiary structure of the proteins. The tertiary structure of the inactive *CHK2* homodimer (PDB code: 3i6w) is shown in Figure 4B (Cai et al. 2009). p.R474 is located away from the ATP-binding region; however, it forms a salt bridge with the well-conserved p.E394 at the end of the activation segment (Fig. 4C). This salt bridge is evolutionarily well-conserved among other kinases. However, the mutation p.R474C destroys this salt bridge and is likely to make the protein unstable (Fig. 4C). Previously, the active *CHK2* homodimer structure (PDB code: 2cn5) with the swapped and ordered activation segment was reported (Fig. 4D; Oliver et al. 2006). Interestingly, the active dimer also has the salt bridge involving p.R474; however, the partner, p.E394, is provided from the other chain. This suggests that protein stability of both inactive and active states might be disturbed by p.R474C. Using prediction models, p.R474C was also predicted to be “disease causing” by MutationTaster2 (Schwarz et al. 2014) and “most likely to interfere with function” by Align GVGD (Mathe et al. 2006).

The tertiary structure of *FCGRT*-immunoglobulin Fc fragment complex was determined. p.R210 contacts the carboxyl terminus of the immunoglobulin Fc fragment. Although there is a salt bridge between p.R210 and the Fc fragment, the carboxyl terminus is usually not important for the overall structure of the protein. In addition, p.R210 is not well conserved, and glutamine (Q) is observed in amino acid position 210 in homologs. Thus, p.R210Q is not likely to affect the function and the structure of the protein.

Figure 4. CHEK2 mutation. (A) Sanger sequencing of p.R474C mutation from patient siblings. (B) Structure of inactive CHEK2 homodimer (PDB code: 3i6w). Most residues in the activation segment are disordered and invisible. (C) Enlarged view of the salt bridge between p.R474 and p.E394. (D) Structure of active CHEK2 homodimer with ADP (PDB code: 2cn5). The activation segment is visible and swapped. (E) Enlarged view of the interchain salt bridge between p.R474 and p.E394. The molecular graphics were generated with UCSF Chimera (Pettersen et al. 2004).

The tertiary structure of SFI1 was partially determined. The amino acid substitution site is outside of the determined structure. The structure model of INPP5J was partially generated using a homologous protein (INPP5B). However, amino acid sequences of the mutated region differ. Thus, evaluating the significance of the mutations in these proteins from their tertiary structures is difficult.

CHEK2 p.R474C Protein Is Poorly Activated in the Cell upon DNA Damage

CHEK2 is a cell cycle checkpoint regulator activated by DNA damage. The above analysis and the function of CHEK2 suggest that CHEK2 is a contributory gene for this familial case. We therefore examined the function of CHEK2 p.R474C with a cell transfection experiment. We introduced expression vectors encoding wild-type or p.R474C CHEK2 cDNA into

Table 4. A list of novel homozygous variants in runs of homozygosity common to both siblings

Position ^a	Ref	Var	Allelic read depth (ref/var)		Gene symbol	RefSeq, CCDS, predicted mutation at nucleotide, and protein level ^b	SIFT ^c	PolyPhen ^c
			FL1	FL2				
Chr 19: 50027791	G	A	0/48	0/42	<i>FCGRT</i>	NM_004107.4, CCDS12770.1, c.629G>A, p.R210Q	Deleterious	Probably damaging
Chr 22: 26388338	G	T	0/96	0/67	<i>MYO18B</i>	NM_032608.5, CCDS54507.1, c.6166G>T, p.V2056L	Tolerated	Benign
Chr 22: 29090061	G	A	0/231	0/187	<i>CHEK2</i>	NM_007194.3, CCDS13843.1, c.1420C>T, p.R474C	Deleterious	Probably damaging
Chr 22: 31522910	A	G	0/26	0/21	<i>INPP5J</i>	NM_001002837.2, CCDS46687.1, c.394A>G, p.S132G	Deleterious	Benign
Chr 22: 31904305	G	A	1/60	0/73	<i>SFI1</i>	NM_001007467.2, CCDS43004.1, c.35G>A, p.S12N	Deleterious	Probably damaging

RefSeq, Reference Sequence Database; CCDS, Consensus Coding DNA Sequence; SIFT, Sorting Intolerant from Tolerant; PolyPhen, Polymorphism Phenotyping.

^aLoci in GRCh37/hg19.

^bA canonical transcript is indicated even if there are several alternative transcripts.

^cThe effects of variants were predicted using the Variant Effect Predictor at Ensembl (<http://www.ensembl.org/info/docs/tools/vep/index.html>).

NIH3T3 cells by the calcium phosphate-DNA precipitation method (Fig. 5). The expression of wild-type CHK2 protein was observed, and the protein was activated by phosphorylation after ultraviolet (UV) exposure. Unlike wild-type CHK2, p.R474C was scarcely expressed or phosphorylated regardless of UV exposure. Thus, CHK2 p.R474C was unstable and poorly activated by DNA damage in the cell.

Variants in Other Disease-Related Genes

We surveyed variants in potential hereditary loci including those in *TP53* (causative gene for Li–Fraumeni syndrome), *BRCA2* (causative gene for hereditary breast/ovarian cancer), and mismatch repair genes (*MSH2*, *MSH6*, *PMS2*, and *EPCAM*, i.e., causative genes for Lynch syndrome), but found only common SNPs. Allele frequencies of these SNPs were 27%–100% in the Japanese population. According to ClinVar, rs1042522 (*TP53*, p.P72R) and rs169547 (*BRCA2*, p.V2466A) are “Benign” or of “Uncertain significance,” and all variants (rs1126497, rs2303424, rs1042821, rs2228006, and rs1805323) in mismatch repair genes are “Benign.” We did not detect any variants in the coding regions of lung cancer–related genes, including *YAP1* and *EGFR*. These genes are not likely affecting our patients’ phenotypes.

Among the variants detected in the runs of homozygosity common to both siblings, five were recorded as disease-associated variants in the HGMD public entries. However, they are related to diabetes or insulin secretion (rs757110 in *ABCC8*, rs5215 and rs5219 in *KCNJ11*), carotid intima media thickness (rs2468844 in *SAA2*), and oligospermia (rs11703684 in *PIWIL3*). The allele frequencies of these variants in the Japanese population are 19%–89%; therefore, they are unlikely to be involved in our patients’ phenotypes.

Figure 5. Protein expression assay of CHEK2. NIH3T3 cells were mock-transfected (None) or transfected with expression vectors containing HA-tagged wild-type (WT) or mutant *CHEK2*. After treatment with or without UV radiation, cell lysates were analyzed by western blotting with an anti-HA-tag antibody (top panels). Alternatively, ectopic CHEK2 protein was immunoprecipitated from the cell lysate with anti-HA epitope antibody and subsequently analyzed by western blotting using antiphosphorylated CHEK2 antibody (second panels from top). CHEK2-P, phosphorylated CHEK2. The bottom panels and the second panels from the bottom are controls. γ -tub, γ -tubulin.

DISCUSSION

CHEK2 is a cell cycle checkpoint regulator activated by DNA damage. Upon DNA damage, CHEK2 is phosphorylated by ataxia telangiectasia mutated (ATM), or ATM- and Rad3-related (ATR) kinases. The activated protein inhibits CDC25C phosphatase, which prevents the cell's entry into mitosis. It has also been shown to stabilize the tumor-suppressor protein p53 leading to cell cycle arrest in G₁. In addition to this main pathway, CHEK2 is involved in various other pathways inside the cell (Antoni et al. 2007; Tung and Silver 2011).

It has been debated in previous studies whether *CHEK2* was a high-penetrance cancer-causative gene. At first, *CHEK2* was claimed to be one of several causative genes for Li-Fraumeni syndrome (Bell et al. 1999). However, one of the reported *CHEK2* mutations was found to be a SNP in the duplicated region of *CHEK2* (Sodha et al. 2000), and it is now generally accepted that *CHEK2* is not a causative gene of Li-Fraumeni syndrome (Sodha et al. 2002). Mutations in *CHEK2* such as *CHEK2**1100delC in the Dutch/Finnish population and p.S428F in the Ashkenazi Jew population are carried by ~1% of people in these populations (Fletcher and Houlston 2010). In particular, *CHEK2**1100delC is prevalent in the Caucasian population, and a large cohort study demonstrated that it was a rare disease-causing variant for breast cancer whose odds ratio for unselected patients was 2.7 (Weischer et al. 2008). The protein resulting from *CHEK2**1100delC lacks the kinase domain, is unstable, and is associated with complete loss of expression of the protein (Bahassi et al. 2007). However, it is difficult to demonstrate that *CHEK2* acts as a tumor-suppressor gene (i.e., functioning through somatic loss or inactivation of the wild-type allele) because of its low risk ratio and low allele frequency. It should be noted that somatic mutations in *CHEK2* are infrequent. For example, in lung cancer, the incidence of *CHEK2* mutations and copy-number variants

is 0.99% (22/2219) and 0.54% (6/1112), respectively (Catalogue of Somatic Mutations in Cancer; <http://cancer.sanger.ac.uk/cosmic>).

Two recent studies reported on the homozygous mutation of *CHEK2**1100delC (Adank et al. 2011; Huijts et al. 2014). Both studies indicated that homozygotes had increased breast cancer risk compared with the heterozygotes of *CHEK2**1100delC. It is important to note that seven of 10 homozygous breast cancer patients developed multiple primary tumors (Adank et al. 2011), and three of five developed contralateral breast cancer (Huijts et al. 2014). van Puijenbroek et al. reported a sporadic case of colorectal cancer with homozygous *CHEK2**1100delC deletion (van Puijenbroek et al. 2005). This patient manifested no significant clinical phenotypes, but died at the relatively early age of 52.

Unlike the Caucasian population, there are no *CHEK2* variants comparable with *CHEK2**1100delC in the Asian population (Chen et al. 2008; Choi et al. 2008). The incidence of inactivating mutations is less in the Asian population. The case described here is a very rare case of homozygous inactivating mutations in *CHEK2* in the Asian population.

In the NHLBI Exome Sequencing Project (<http://evs.gs.washington.edu/EVS/>), heterozygous p.R474H variants (by a base change in neighboring nucleotide position of the p.R474C variant) had been detected in a European- and African-American population. Allele frequency in this database (3733 individuals) is 0.03%. During preparation of this manuscript, a British individual with a heterozygous p.R474C variant was recorded in the 1000 Genomes Project phase 3 (<http://www.1000genomes.org/>). Allele frequency in the 1000 Genomes Project (2503 individuals including 504 East Asian) is 0.02%. So far, no homozygous variant of p.R474 has been detected in healthy individuals.

The main question is whether the homozygous inactivation of the *CHEK2* gene constitutes a new disease entity. Although other reported cases did not manifest such strong clinical phenotypes as our case study, there was high incidence of multiple primary tumors. With regard to the sporadic case, if a suitable treatment was performed, the patient might have developed cancers in other organs (van Puijenbroek et al. 2005). Although heterozygous *CHEK2* mutations were previously denied as the cause of multiple familial cancers, these data suggest the possibility that homozygous inactivation of this protein may lead to multi-organ cancer. A mouse model in which the wild-type *Chek2* has been replaced by a *CHEK2**1100delC allele exhibited a similar phenotype: mice homozygous for *CHEK2**1100delC produced significantly more tumors than wild-type mice, whereas heterozygous mice were not statistically different from wild type (Bahassi et al. 2009). The severity of the symptoms is likely to be variable for *CHEK2* mutations, and accumulation of more cases will clarify *CHEK2*'s role in cancer development.

It should be noted that the siblings' mother had lung cancer and their father had prostate and gastric cancer and FL1's son had neuroblastoma, subsequently leading to their death. Given this family history, it is possible that there are additional contributory genes and an autosomal-dominant syndrome, which is the more common mode of inheritance in hereditary cancer syndromes. Such genes might be missed in the variant analysis because of no reliable Asian controls or small exon level copy-number variants that are not detectable by exome sequencing and SNP arrays.

METHODS

DNA Extraction

Genomic DNA from peripheral blood monocytes was extracted with a QIAamp DNA Mini Kit (QIAGEN). DNA concentration was determined with the use of a Qubit dsDNA HS Assay Kit (Life Technologies). DNA samples were examined by electrophoresis on 1% agarose gels to confirm a lack of significant degradation.

Tissue Preparation

Formalin-fixed, paraffin-embedded tissue sections were prepared as part of routine medical practices. In addition to hematoxylin/eosin, the sections were stained with anti-TTF1 and anti-Napsin A.

SNP Array Experiment

SNP array experiments were performed with an Illumina Omni1-Quad chip (which interrogates more than one million loci). Base-calling and calculation of BAF and LRR (or $\log_2(R_{\text{observed}}/R_{\text{expected}})$, where R is probe intensity) were done by GenomeStudio (Illumina). Because BAF is one allele frequency of two alleles, its value is around 0 or 1 for homozygotes and around 0.5 for heterozygotes. R_{expected} is interpolated from the observed allelic ratio with respect to the canonical genotype clusters (Peiffer et al. 2006), and LRR represents relative copy-number status of the position. For normal-copy-number regions, the value is around 0. Positive and negative values are gain and loss changes, respectively. The mean SNP call rate was >99.6%. Runs of homozygous genotypes within individuals were screened using PLINK (Purcell et al. 2007) with homozygous segment criteria: 1000 kb length, 100 SNPs, 50 kb/SNP density, and 1000 kb largest gap. The circle plot diagram shown in Figure 3 was drawn using Circos (Krzywinski et al. 2009).

Exome Sequencing and Data Analysis

Patients' DNA fragments of exonic regions were enriched with SureSelect Human All Exon 50 M kit (Agilent). Recovered DNA fragments were sequenced as 90-bp paired-end reads on an Illumina HiSeq 2000. Total reads obtained were 195,020,136 and 198,040,764 for patient FL1 and FL2, respectively. These exome sequencing procedures were done by BGI exome service. We aligned paired-end reads to the human reference genome (hg19) with Burrows-Wheeler alignment (BWA) (Li and Durbin 2009) and created .bam files using SAMtools (Li et al. 2009). Base call quality recalibration and local realignment were also performed using the Genome Analysis Toolkit (GATK) (DePristo et al. 2011). Sequence variants were detected by UnifiedGenotyper in GATK (DePristo et al. 2011). Variants in positions with low coverage (less than eight reads) were discarded. Annotation for detected variants was performed using ANNOVAR (Wang et al. 2010). Novel and known variants were discriminated using variant data: dbSNP build 135 (<http://www.ncbi.nlm.nih.gov/SNP/>), phase 1 data of 1000 Genomes Project (<http://www.1000genomes.org/>), and 5400 exome data of Exome Sequencing Project (<https://esp.gs.washington.edu/drupal/>).

Construction of Expression Vectors and Protein Expression Analysis

We amplified *CHEK2* coding sequences from cDNAs of both a patient with the mutant gene (p.R474C) and a person with wild-type *CHEK2*, using a 5'-side primer with HA-tag, 5'-AGA TCT CTC GAG ACC ATG TAC CCA TAC GAT GTT CCA GAT TAC GCT TCT CGG GAG TCG GAT GTT GAG G-3', and a 3'-side primer, 5'-GTT AAC GAA TTC CGG AGT TCA CAA CAC AGC AGC A-3'. *CHEK2* fragments were inserted into the XhoI-EcoRI site of pMSCVpuro (Clontech). *CHEK2* coding regions in plasmid constructs were confirmed to be same to RefSeq NM_007194.3 except p.R474C using Sanger sequencing. The plasmid constructs were transfected into NIH3T3 cells, and protein expression was analyzed as described in our previous work (Yoshida et al. 2013).

ADDITIONAL INFORMATION

Data Deposition and Access

The SNP-genotyping and exome sequencing data were deposited in the Japanese Genotype-phenotype Archive (JGA) under accession number JGAS00000000057 (<https://ddbj.nig.ac.jp/jga/viewer/view/studies>) under Type I security. The CHEK2 variant p.R474C has been deposited in the ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar/>) database under accession number SCV000282240.

Ethics Statement

Written informed consent for research and data sharing was obtained from both patients. This study was approved by the ethics committee of the Osaka Medical Center for Cancer and Cardiovascular Diseases (Approval No. 1603315234).

Acknowledgments

This work was partly supported by the Ministry of Education, Culture, Sports, Science & Technology in Japan (JSPS KAKENHI) under Grant Number 25430180, the Osaka Community Foundation, the Charitable Trust Osaka Cancer Research Foundation, and the Osaka Medical Research Foundation for Intractable Diseases (Y.K.). This work was also partly supported by the Platform for Drug Discovery, Informatics, and Structural Life Science from the Japan Agency for Medical Research and Development (T.K.).

Referees

Raymond D. Kim
Anonymous

Received February 25, 2016;
accepted in revised form July 26,
2016.

Author Contributions

K.Ka. and Y.K. conceived and designed the experiments. Y.K., N.Y.K., I.N., and J.K. performed the experiments. Y.K., T.K., J.K., and K.Ka. analyzed the data. J.O., M.H., and K.Ko. contributed materials/analysis tools. K.Ka. and Y.K. wrote the manuscript.

REFERENCES

- Adank MA, Jonker MA, Kluijdt I, van Mil SE, Oldenburg RA, Mooi WJ, Hogervorst FB, van den Ouweland AM, Gille JJ, Schmidt MK, et al. 2011. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women. *J Med Genet* **48**: 860–863.
- Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. 2010. A method and server for predicting damaging missense mutations. *Nat Methods* **7**: 248–249.
- Antoni L, Sodha N, Collins I, Garrett MD. 2007. CHK2 kinase: cancer susceptibility and cancer therapy—two sides of the same coin? *Nat Rev Cancer* **7**: 925–936.
- Bahassi el M, Penner CG, Robbins SB, Tichy E, Feliciano E, Yin M, Liang L, Deng L, Tischfield JA, Stambrook PJ. 2007. The breast cancer susceptibility allele CHEK2*1100delC promotes genomic instability in a knock-in mouse model. *Mutat Res* **616**: 201–209.
- Bahassi el M, Robbins SB, Yin M, Boivin GP, Kuiper R, van Steeg H, Stambrook PJ. 2009. Mice with the CHEK2*1100delC SNP are predisposed to cancer with a strong gender bias. *Proc Natl Acad Sci* **106**: 17111–17116.
- Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, et al. 1999. Heterozygous germ line hCHK2 mutations in Li–Fraumeni syndrome. *Science* **286**: 2528–2531.
- Cai Z, Chehab NH, Pavletich NP. 2009. Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase. *Mol Cell* **35**: 818–829.
- Chen W, Yurong S, Liansheng N. 2008. Breast cancer low-penetrance allele 1100delC in the CHEK2 gene: not present in the Chinese familial breast cancer population. *Adv Ther* **25**: 496–501.
- Choi DH, Cho DY, Lee MH, Park HS, Ahn SH, Son BH, Haffty BG. 2008. The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation. *Breast Cancer Res Treat* **112**: 569–573.

- DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, et al. 2011. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet* **43**: 491–498.
- Fletcher O, Houlston RS. 2010. Architecture of inherited susceptibility to common cancer. *Nat Rev Cancer* **10**: 353–361.
- Huijts PE, Hollestelle A, Balliu B, Houwing-Duistermaat JJ, Meijers CM, Blom JC, Ozturk B, Krol-Warmerdam EM, Wijnen J, Berns EM, et al. 2014. CHEK2*1100delC homozygosity in the Netherlands—prevalence and risk of breast and lung cancer. *Eur J Hum Genet* **22**: 46–51.
- Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, Jones SJ, Marra MA. 2009. Circos: an information aesthetic for comparative genomics. *Genome Res* **19**: 1639–1645.
- Kumar P, Henikoff S, Ng PC. 2009. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc* **4**: 1073–1081.
- Landrum MJ, Lee JM, Benson M, Brown G, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Hoover J, et al. 2016. ClinVar: public archive of interpretations of clinically relevant variants. *Nucleic Acids Res* **44**: D862–D868.
- Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows–Wheeler transform. *Bioinformatics* **25**: 1754–1760.
- Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, 1000 Genome Project Data Processing Subgroup. 2009. The sequence alignment/map format and SAMtools. *Bioinformatics* **25**: 2078–2079.
- Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, et al. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. *Science* **250**: 1233–1238.
- Mathe E, Olivier M, Kato S, Ishioka C, Hainaut P, Tavtigian SV. 2006. Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. *Nucleic Acids Res* **34**: 1317–1325.
- McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. 2010. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. *Bioinformatics* **26**: 2069–2070.
- Oliver AW, Paul A, Boxall KJ, Barrie SE, Aherne GW, Garrett MD, Mitnacht S, Pearl LH. 2006. Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange. *EMBO J* **25**: 3179–3190.
- Peiffer DA, Le JM, Steemers FJ, Chang W, Jenniges T, Garcia F, Haden K, Li J, Shaw CA, Belmont J, et al. 2006. High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping. *Genome Res* **16**: 1136–1148.
- Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. 2004. UCSF Chimera—a visualization system for exploratory research and analysis. *J Comput Chem* **25**: 1605–1612.
- Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, et al. 2007. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* **81**: 559–575.
- Schwarz JM, Cooper DN, Schuelke M, Seelow D. 2014. MutationTaster2: mutation prediction for the deep-sequencing age. *Nat Methods* **11**: 361–362.
- Sodha N, Williams R, Mangion J, Bullock SL, Yuille MR, Eeles RA. 2000. Screening hCHK2 for mutations. *Science* **289**: 359.
- Sodha N, Houlston RS, Bullock S, Yuille MA, Chu C, Turner G, Eeles RA. 2002. Increasing evidence that germline mutations in CHEK2 do not cause Li–Fraumeni syndrome. *Hum Mutat* **20**: 460–462.
- Tung N, Silver DP. 2011. Chek2 DNA damage response pathway and inherited breast cancer risk. *J Clin Oncol* **29**: 3813–3815.
- van Puijtenbroek M, van Asperen CJ, van Mil A, Devilee P, van Wezel T, Morreau H. 2005. Homozygosity for a CHEK2*1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype. *J Pathol* **206**: 198–204.
- Vasen HF, Watson P, Mecklin JP, Lynch HT. 1999. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. *Gastroenterology* **116**: 1453–1456.
- Wang K, Li M, Hakonarson H. 2010. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res* **38**: e164.
- Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG. 2008. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. *J Clin Oncol* **26**: 542–548.
- Yoshida A, Yoneda-Kato N, Kato JY. 2013. CSN5 specifically interacts with CDK2 and controls senescence in a cytoplasmic cyclin E-mediated manner. *Sci Rep* **3**: 1054.

Homozygous inactivation of *CHEK2* is linked to a familial case of multiple primary lung cancer with accompanying cancers in other organs

Yoji Kukita, Jiro Okami, Noriko Yoneda-Kato, et al.

Cold Spring Harb Mol Case Stud 2016, **2**: a001032 originally published online August 2, 2016
Access the most recent version at doi:[10.1101/mcs.a001032](https://doi.org/10.1101/mcs.a001032)

References This article cites 33 articles, 9 of which can be accessed free at:
<http://molecularcasestudies.cshlp.org/content/2/6/a001032.full.html#ref-list-1>

License This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted reuse and redistribution provided that the original author and source are credited.

Email Alerting Service Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).